Aptorum announces DiamiR-AlzLabs collaboration on blood-based Alzheimer’s biomarkers

Aptorum Group

Aptorum Group

APM

0.00
  • Aptorum Group disclosed a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics on blood-based Alzheimer’s biomarkers.
  • The study will generate protein and microRNA biomarker data from plasma samples with amyloid status confirmed by amyloid PET.
  • DiamiR plans to assess the biomarker panels alone or combined with its CogniMIR microRNA platform for potential clinical testing and biopharma services.
  • The companies expect Aptorum’s all-stock merger with DiamiR to close before fiscal 2027, pending remaining closing conditions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606220800PRIMZONEFULLFEED9750322) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.